Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer

被引：0
|
作者：
Y. F. Yu
Y. Wang
T. P. Fu
K. Chen
J. Q. Liu
H. R. Yao
机构：
[1] Sun Yat-sen Memorial Hospital,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center
[2] Sun Yat-sen University,Department of Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
[3] Sun Yat-sen University Cancer Center,Department of Oncology
[4] Sun Yat-sen Memorial Hospital,undefined
[5] Sun Yat-sen University,undefined
来源：
Breast Cancer Research and Treatment | 2018年 / 168卷
关键词：
Metastatic breast cancer; HER2-positive; Trastuzumab; Single-agent chemotherapy; Doublet-agent chemotherapy; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：337 / 348
页数：11
相关论文
共 50 条
  • [1] Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
    Yu, Y. F.
    Wang, Y.
    Fu, T. P.
    Chen, K.
    Liu, J. Q.
    Yao, H. R.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : 337 - 348
  • [2] Trastuzumab combined with doublet or single-agent chemotherapy as a first-line treatment for HER2-positive metastatic breast cancer.
    Yu, Yunfang
    Wang, Ying
    Chen, Kai
    Fu, Tuping
    Yao, Herui
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [4] Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
    Arteaga, CL
    BREAST CANCER RESEARCH, 2003, 5 (02) : 96 - 100
  • [5] Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
    Carlos L Arteaga
    Breast Cancer Research, 5
  • [6] Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer
    Rastogi, Priya
    Davidson, Nancy E.
    ONKOLOGIE, 2010, 33 (8-9): : 420 - 421
  • [7] First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer:: a preliminary report
    Vogel, C
    Cobleigh, MA
    Tripathy, D
    Gutheil, JC
    Harris, LN
    Fehrenbacher, L
    Slamon, DJ
    Murphy, M
    Novotny, WF
    Burchmore, M
    Shak, S
    Stewart, SJ
    EUROPEAN JOURNAL OF CANCER, 2001, 37 : S25 - S29
  • [8] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Farhat, Fadi
    Kattan, Joseph G.
    Ghosn, Marwan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 1069 - 1077
  • [9] An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer
    Cardoso, Fatima
    Canon, Jean-Luc
    Amadori, Dino
    Aldrighetti, Daniela
    Machiels, Jean-Pascal
    Bouko, Yasmina
    Verkh, Lev
    Usari, Tiziana
    Kern, Kenneth A.
    Giorgetti, Carla
    Dirix, Luc
    BREAST, 2012, 21 (06): : 716 - 723
  • [10] Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Dias, Zetina L.
    Gaui, M.
    Otero Reyes, D.
    Jassem, J.
    Button, P.
    Bell, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S33 - S33
12345